Healthcare -
Biotechnology - NASDAQ - US
$ 3.99
2.58 %
$ 222 M
Market Cap
-2.52
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Foghorn Therapeutics Inc.
| Revenue | 22.6 M |
| Cost Of Revenue | 3.12 M |
| Gross Profit | 19.5 M |
| Operating Expenses | 125 M |
| Operating Income | -103 M |
| Other Expenses | -16.1 M |
| Net Income | -86.6 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 22.6 | 34.2 | 19.2 | 1.3 | 0.4 | 0 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 3.1 | 109.7 | 19.2 K | 7.5 | 57.7 | 1.8 | 0.4 |
| Gross Profit | 19.5 | (75.5) | 19.2 | (6.2) | (57.3) | (1.8) | (0.4) |
| OPERATING INCOME | |||||||
| Operating Expenses | 125.3 | 142.1 | 136.4 | 102.1 | 69.0 | 51.1 | 26.0 |
| Selling, General and Administrative Expenses | 28.4 | 32.4 | 30.7 | 21.7 | 11.2 | 6.7 | 4.8 |
| Research and Development Expenses | 94.5 | 109.7 | 105.6 | 80.3 | 57.7 | 44.4 | 21.2 |
| Operating Income | (102.7) | (107.9) | (117.1) | (100.7) | (68.5) | (51.1) | (26.0) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 0 | 0 | 1.9 | 1.0 | 0.5 | 0.4 |
| Total Other Income | 16.1 | 13.7 | 8.3 | (0.6) | (0.3) | 44 K | (0.3) |
| Pre-Tax Income | (86.6) | (94.2) | (108.9) | (101.3) | (68.8) | (51.1) | (26.3) |
| NET INCOME | |||||||
| Tax Provision | 0 | 4.2 | 8.26 K | 1.9 | 1.0 | 0.5 | 83 K |
| Net Income | (86.6) | (98.4) | (108.9) | (103.2) | (69.8) | (51.7) | (26.3) |
| EPS | 1.58 | 2.34 | 2.62 | 2.78 | 1.9 | 1.4 | 1.34 |